Biohaven Stock Earnings Estimates Raised by HC Wainwright

Biohaven Ltd. (NYSE:BHVN) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Biohaven in a report issued on Monday, November 2nd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($3.00) per share for the year, up from their prior forecast of ($3.44). HC Wainwright has a “Neutral” rating and a $10.00 price objective on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.11) per share. HC Wainwright also issued estimates for Biohaven’s Q4 2026 earnings at ($0.35) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($2.14) EPS, FY2029 earnings at ($1.40) EPS and FY2030 earnings at $1.86 EPS.

Several other equities research analysts have also recently weighed in on BHVN. Robert W. Baird set a $48.00 target price on Biohaven in a report on Thursday, October 22nd. Royal Bank Of Canada lifted their price target on Biohaven from $19.00 to $22.00 and gave the stock a “sector perform” rating in a research note on Friday, October 23rd. Canaccord Genuity Group boosted their price objective on Biohaven from $21.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, October 30th. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. Finally, Citigroup reiterated a “buy” rating on shares of Biohaven in a report on Friday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Biohaven currently has an average rating of “Moderate Buy” and an average price target of $20.06.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $15.22 on Thursday. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -3.94 and a beta of 1.36. The stock’s 50-day moving average is $13.71 and its 200 day moving average is $12.30. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.24. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15).

Institutional Trading of Biohaven

Large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC purchased a new position in Biohaven during the 3rd quarter valued at $135,000. Profund Advisors LLC increased its position in shares of Biohaven by 5.6% during the third quarter. Profund Advisors LLC now owns 57,036 shares of the company’s stock valued at $761,000 after buying an additional 3,018 shares during the period. Sigma Planning Corp raised its stake in Biohaven by 43.1% in the third quarter. Sigma Planning Corp now owns 19,944 shares of the company’s stock worth $266,000 after buying an additional 6,008 shares in the last quarter. Sterling Capital Management LLC raised its stake in Biohaven by 847.5% in the third quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock worth $59,000 after buying an additional 3,975 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in Biohaven by 2.4% in the third quarter. Inspire Investing LLC now owns 47,089 shares of the company’s stock worth $629,000 after buying an additional 1,113 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.